Clinical Trial for Prevention of Cisplatin-Induced Renal Nephrotoxicity
Phase 1
Recruiting
- Conditions
- Cancer
- Registration Number
- JPRN-jRCTs041220021
- Lead Sponsor
- Kondo Masashi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Has provided written consent for participation
- Age 20 or greater at the time of consent
- Has never received cisplatin-containing chemotherapy
- Scheduled for chemotherapy with cisplatin only or cisplatin plus other anticancer agents under hospitalization
- Lung, head and neck, and other cancer patients scheduled for cisplatin regimens with doses of 80 mg/m2 or higher in patients with
Exclusion Criteria
- Presence of renal dysfunction: eGFR<60 mL/min/1.73 m2
- Pregnant or possibly pregnant women
- Lactating women
- With a history of hypersensitivity to flopropione
- Deemed ineligible for the study as determined by the principal investigator or a co-investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method